The Progress In The Research Of Molecular-targeted Drugs For Non-small Cell Lung Cancer

Lung cancer is one of the most malignant tumors in the world,for its high rate of morbidity and mortality.Non small cell lung cancer(NSCLC)accounts for eighty percent to eighty-five percent of the incidence of the diseace.After the treatment of surgery,radiotherapy and chemotherapy,the five-year survival rate is still lower than fifteen percent.Molecule-targeted drug is a new kind of treatment.Compared with traditional surgery,radiotherapy and chemotherapy,It might improve the clinical efficency,cause less toxicity and side effects,and improve the quality of life of patients,for it could combine to the specific target of the tumor cell,as to affect precised strike to tumor cells with less damage to normal cells.Molecule-targeted treatment has become a hot spot in the research of the NSCLC drug therapy.Molecular targeted drugs for the treatment of NSCLC include EGFR tyrosine kinase inhibitors,ALK inhibitors,BRAF inhibitors,MET inhibitors,and multiple target inhibitors and so on.In this paper,through the scanning of articles of the lasted five years,the progress in the research of molecular targeted drugs for non-small cell lung cancer would be reviewed.